PMID- 28374162
OWN - NLM
STAT- MEDLINE
DCOM- 20170815
LR  - 20181202
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 96
IP  - 6
DP  - 2017 Jun
TI  - Peripheral blood cytogenetics allows treatment monitoring and early 
      identification of treatment failure to lenalidomide in MDS patients: results of 
      the LE-MON-5 trial.
PG  - 887-894
LID - 10.1007/s00277-017-2983-0 [doi]
AB  - Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic 
      syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received 
      lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 
      (EudraCT:2008-001866-10) of the University of Duesseldorf, Germany. Cytogenetic 
      monitoring was performed by chromosome banding analyses (CBA) of BM cells and 
      fluorescence in situ hybridization (FISH) analyses of peripheral blood (PB) 
      mononuclear CD34+ cells using extended probe panels. Out of 144 patients screened 
      for study enrollment, 24% failed to meet inclusion criteria due to cytogenetic 
      findings. Eighty-seven patients were followed with a median observation time of 
      30 months. Cytogenetic response detected by FISH and CBA in 74 and 66% of 
      patients, respectively, was predictive for hematologic response as well as of 
      high prognostic relevance. After 2 years, AML rate was 8% for all patients. 
      Karyotype evolution was detected in 21 (FISH)-34% (CBA) of patients associated 
      with significantly shorter AML-free survival. Disease progression was first 
      detectable on the cytogenetic level on average 5-6 months before recurrence of 
      transfusion dependence. Our data show for the first time in a prospective setting 
      that a cytogenetic monitoring from the PB helps to early identify treatment 
      failure and progressive disease in lenalidomide-treated patients to improve 
      clinical management. TRIAL REGISTRATION: EudraCT:2008-001866-10.
FAU - Braulke, Friederike
AU  - Braulke F
AD  - Department of Hematology and Medical Oncology, University Medicine of Goettingen, 
      Robert-Koch-Str. 40, 37075, Goettingen, Germany. 
      friederike.braulke@med.uni-goettingen.de.
FAU - Schulz, Xenia
AU  - Schulz X
AD  - Department of Medical Statistics, University Medicine of Goettingen, Goettingen, 
      Germany.
FAU - Germing, Ulrich
AU  - Germing U
AD  - Department of Hematology and Oncology, University of Duesseldorf, Duesseldorf, 
      Germany.
FAU - Schuler, Esther
AU  - Schuler E
AD  - Department of Hematology and Oncology, University of Duesseldorf, Duesseldorf, 
      Germany.
FAU - Platzbecker, Uwe
AU  - Platzbecker U
AD  - Department of Hematology and Oncology, University of Dresden, Dresden, Germany.
FAU - Nolte, Florian
AU  - Nolte F
AD  - Department of Hematology and Oncology, Medical Faculty Mannheim of the University 
      of Heidelberg, Mannheim, Germany.
FAU - Hofmann, Wolf-Karsten
AU  - Hofmann WK
AD  - Department of Hematology and Oncology, Medical Faculty Mannheim of the University 
      of Heidelberg, Mannheim, Germany.
FAU - Giagounidis, Aristoteles
AU  - Giagounidis A
AD  - Department of Hematology and Oncology, Marienhospital, Duesseldorf, Germany.
FAU - Gotze, Katharina
AU  - Gotze K
AD  - Department of Hematology and Oncology, Technical University of Munich, Munich, 
      Germany.
FAU - Lubbert, Michael
AU  - Lubbert M
AD  - Department of Hematology and Oncology, University of Freiburg Medical Center, 
      Freiburg, Germany.
FAU - Schlenk, Richard F
AU  - Schlenk RF
AD  - Department of Hematology and Oncology, University of Ulm, Germany, now National 
      Center of Tumor Diseases, Heidelberg, Germany.
FAU - Schanz, Julie
AU  - Schanz J
AD  - Department of Hematology and Medical Oncology, University Medicine of Goettingen, 
      Robert-Koch-Str. 40, 37075, Goettingen, Germany.
FAU - Bacher, Ulrike
AU  - Bacher U
AD  - Department of Hematology and Medical Oncology, University Medicine of Goettingen, 
      Robert-Koch-Str. 40, 37075, Goettingen, Germany.
FAU - Ganser, Arnold
AU  - Ganser A
AD  - Department of Hematology, Hemostaseology and Stem Cell Transplantation, Hannover 
      Medical School (MHH), Hannover, Germany.
FAU - Busche, Guntram
AU  - Busche G
AD  - Institute of Pathology, Hannover Medical School (MHH), Hannover, Germany.
FAU - Letsch, Anne
AU  - Letsch A
AD  - Departement of Hematology and Oncology, Charite University Medical Center Berlin, 
      Berlin, Germany.
FAU - Schafhausen, Philippe
AU  - Schafhausen P
AD  - Department of Oncology, Hematology, BMT with section Pneumology, Hubertus Wald 
      Cancer Center, Medical Center Hamburg-Eppendorf, Hamburg, Germany.
FAU - Bug, Gesine
AU  - Bug G
AD  - Department of Internal Medicine II, Hematology and Oncology, Johann Wolfgang 
      Goethe University of Frankfurt, Frankfurt, Germany.
FAU - Brummendorf, Tim H
AU  - Brummendorf TH
AD  - Department of Hematology and Oncology, Hemostaseology and SCT, University 
      Hospital RWTH Aachen, Aachen, Germany.
FAU - Haas, Rainer
AU  - Haas R
AD  - Department of Hematology and Oncology, University of Duesseldorf, Duesseldorf, 
      Germany.
FAU - Trumper, Lorenz
AU  - Trumper L
AD  - Department of Hematology and Medical Oncology, University Medicine of Goettingen, 
      Robert-Koch-Str. 40, 37075, Goettingen, Germany.
FAU - Shirneshan, Katayoon
AU  - Shirneshan K
AD  - Department of Hematology and Medical Oncology, University Medicine of Goettingen, 
      Robert-Koch-Str. 40, 37075, Goettingen, Germany.
FAU - Haase, Detlef
AU  - Haase D
AD  - Department of Hematology and Medical Oncology, University Medicine of Goettingen, 
      Robert-Koch-Str. 40, 37075, Goettingen, Germany.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170403
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antigens, CD34)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antigens, CD34/blood
MH  - Chromosome Banding
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 5/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Germany
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Lenalidomide
MH  - Leukemia, Myeloid/diagnosis/genetics
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*drug therapy/genetics
MH  - Prognosis
MH  - Thalidomide/*analogs & derivatives/therapeutic use
MH  - Treatment Failure
OTO - NOTNLM
OT  - 5q-deletion
OT  - CD34+ cells
OT  - Chromosome banding analysis
OT  - Clonal evolution
OT  - Fluorescence in situ hybridization (FISH)
OT  - Myelodysplastic syndromes (MDS)
EDAT- 2017/04/05 06:00
MHDA- 2017/08/16 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/01/24 00:00 [received]
PHST- 2017/03/22 00:00 [accepted]
PHST- 2017/04/05 06:00 [pubmed]
PHST- 2017/08/16 06:00 [medline]
PHST- 2017/04/05 06:00 [entrez]
AID - 10.1007/s00277-017-2983-0 [pii]
AID - 10.1007/s00277-017-2983-0 [doi]
PST - ppublish
SO  - Ann Hematol. 2017 Jun;96(6):887-894. doi: 10.1007/s00277-017-2983-0. Epub 2017 
      Apr 3.